Quantcast

Latest Eszopiclone Stories

2010-03-22 12:12:00

BALTIMORE, March 22 /PRNewswire/ -- Lupin Pharmaceuticals, Inc. (LPI) announced today that it has received tentative approval for the Company's Abbreviated New Drug Application (ANDA) for Eszopiclone tablets, 1 mg, 2 mg and 3 mg from the U.S. Food and Drug Administration (USFDA). Lupin's Eszopiclone tablets are the AB-rated generic equivalent of Sepracor's LUNESTA® tablets, indicated for the treatment of insomnia. The brand product had annual sales of approximately $761...

2010-01-18 08:00:00

WALTHAM, Mass., Jan. 18 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, despite potential safety concerns, Jazz Pharmaceuticals/UCB's sodium oxybate (JZP-6) will account for more than 15 percent of the fibromyalgia drug market in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. Sodium oxybate has demonstrated robust efficacy in Phase III clinical trials...

2009-11-09 09:25:41

Electronic alerts persuade clinicians to switch from costly drugs to generic brands Simple computerized alerts can help curb the impulse to prescribe unnecessarily expensive, heavily marketed drugs, according to a study in the August issue of Journal of General Internal Medicine. The study found that when clinicians received computerized alerts, which compared medication brands, they changed 23.3 percent of prescriptions for four heavily marketed sleep medications to comparable generic...

917469fd509ba84ce2bb795a1761564a1
2009-10-23 06:50:00

U.S. drug labels often omit key information about a medicine's effectiveness and the severity of its side effects, according to a commentary written by two doctors in the New England Journal of Medicine. Such omission of data can result in some medicines appearing safer and more effective than they actually are, wrote Drs. Lisa Schwartz and Steven Woloshin of the Dartmouth Institute for Health Policy and Clinical Practice in Hanover, New Hampshire. "The most direct way that the FDA...

2009-06-08 11:34:39

 Men with insomnia and sleep duration of six or fewer hours of nightly sleep are at an increased risk for mortality, according to a research abstract that will be presented on Monday, June 8, at SLEEP 2009, the 23rd Annual Meeting of the Associated Professional Sleep Societies.Results indicate that compared to people who sleep six hours or more, men with insomnia and less than six hours of nightly sleep were at highest risk of mortality. The mortality rate of the sample was 19.6 percent...

2009-01-16 12:32:00

ANN ARBOR, Mich., Jan. 16 /PRNewswire/ -- Use of prescription sleep aids nearly tripled among 18- to 24-year-olds between 1998 and 2006, according to a study released today by the Healthcare business of Thomson Reuters. During the study period, the average length of time sleep aids were used by adults under age 45 increased more than 40 percent -- rising from 64 days in 1998 to 93 days in 2006. "Insomnia, a condition traditionally associated with older adults, appears to be...

fa1ba12e98af16b03725744acd26cf5d1
2009-01-16 06:55:00

Need the help of a pill to catch some zzz's? According to a new study you're not alone; the use of prescription sleep aids nearly tripled among young adults between 1998 and 2006."Insomnia, a condition traditionally associated with older adults, appears to be causing larger numbers of young adults to turn to prescription sleep aids, and to depend on them for longer periods of time," said William Marder, senior vice president and general manager for the healthcare business of Thomson Reuters,...

2008-10-28 06:00:11

US-based pharmaceutical company Sepracor has announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion recommending to grant a marketing authorization for Lunivia brand eszopiclone in the EU for the treatment of insomnia. The EU labeling provides for patients who require longer-term therapy to be treated for up to six months, with the usual course of therapy for typical patients being short term. Lunivia is marketed in the US...

2008-10-24 06:00:24

Sepracor Inc. (Nasdaq: SEPR) today announced that the EMEA's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending to grant a marketing authorization for LUNIVIA(R) brand eszopiclone in the European Union (EU) for the treatment of insomnia. The EU labeling provides for patients who require longer-term therapy to be treated for up to six months, with the usual course of therapy for typical patients being short-term. LUNIVIA is marketed in the U.S....

2008-09-24 18:00:40

Sepracor Inc. (Nasdaq: SEPR) announced that positive data from three Phase III studies presented today at the 8th European Congress of Epileptology in Berlin, demonstrated that eslicarbazepine acetate, a novel once-daily anti-epileptic agent, significantly reduced the frequency of partial seizures in patients with refractory partial epilepsy, in combination with other anti-epileptic agents.(1), (2), (3) In addition, treatment with eslicarbazepine acetate significantly improved patient...


Word of the Day
tesla
  • The unit of magnetic flux density in the International System of Units, equal to the magnitude of the magnetic field vector necessary to produce a force of one newton on a charge of one coulomb moving perpendicular to the direction of the magnetic field vector with a velocity of one meter per second. It is equivalent to one weber per square meter.
This word is named for Nikola Tesla, the inventor, engineer, and futurist.